Lacidipine Double-E Pharma (Lacidipine)

Lacidipine belongs to the dihydropyridine class of calcium‑channel blockers. It blocks L‑type calcium channels in arterial smooth muscle, which reduces calcium entry, causes vasodilation, and lowers peripheral vascular resistance, resulting in a decrease in systemic blood pressure.

The appropriate dose of Lacidipine Double-E Pharma is determined by the prescribing healthcare professional based on the individual’s blood‑pressure profile, age, renal and hepatic function, and concomitant medications. Patients should follow the prescriber’s instructions exactly.

Safety of lacidipine in pregnancy and lactation has not been established. It is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their physician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lacidipine is a dihydropyridine calcium‑channel blocker, similar to amlodipine but with a longer half‑life and a slightly different side‑effect profile. Compared with ACE inhibitors or beta‑blockers, it primarily causes vasodilation without affecting heart rate, making it useful when a strong peripheral vasodilator is needed.

Lacidipine tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture and direct sunlight, and keep out of reach of children.

The medication is taken orally, usually once daily, with a full glass of water. It can be taken with or without food, but patients should follow the prescribing physician’s guidance regarding timing relative to meals.

Serious adverse events include severe hypotension, which can cause fainting or shock, hepatic dysfunction manifested by abnormal liver enzymes, and allergic reactions such as rash, urticaria or angioedema that require immediate medical attention.

Patients with known hypersensitivity to lacidipine or any component of the tablet, those with severe hypotension, or individuals with uncontrolled heart failure should avoid this medication. A healthcare professional should evaluate any other contraindications before prescribing.